What is the recommended dosing, titration, monitoring, and safety considerations for alpelisib (Vijoice®, generic alpelisib) in a 12‑17‑year‑old patient with confirmed PIK3CA‑related infiltrating lipomatosis?

Alpelisib for Adolescent with PIK3CA-Related Infiltrating Lipomatosis

For a 12-17 year old patient with confirmed PIK3CA-related infiltrating lipomatosis, start alpelisib (Vijoice®) at 50 mg orally once daily with food, and after 24 weeks consider dose escalation to 125 mg once daily for response optimization. 1

Initial Dosing and Titration

Starting Dose

• Initial dose: 50 mg once daily for all pediatric patients aged 2 to <18 years 1
• Administer with food at approximately the same time each day
• Available as tablets (50 mg, 125 mg, 200 mg) or oral granules (50 mg packets)

Dose Escalation Strategy

• After 24 weeks of treatment at 50 mg: Consider increasing to 125 mg once daily for clinical/radiological response optimization in patients ≥6 years old 1
• This titration is specifically recommended for adolescents in the 6 to <18 year age bracket
• When the patient turns 18 years old, consider gradual dose increase up to the adult dose of 250 mg 1

Important caveat: Recent pharmacokinetic data shows the fixed 50 mg dose produces highly variable drug exposure (CV=58%) in children, with AUC correlating with weight 2. However, the FDA-approved dosing remains weight-independent until further data emerge.

Pre-Treatment Screening (Critical)

Mandatory Baseline Testing

• HbA1c: Must be <6.5% (patients with uncontrolled diabetes are contraindicated) 3
• Fasting glucose
• Assess for diabetes risk factors including obesity 3
• Patients with well-controlled type 2 diabetes can be treated, but those with uncontrolled diabetes should NOT receive alpelisib 3

Monitoring Protocol

Intensive Early Monitoring (Weeks 1-4)

Weekly laboratory and symptom monitoring for the first 4 weeks is critical to avoid serious toxicity 3. This timing is based on the median onset of:

• Grade 3 hyperglycemia: 15 days 3
• Grade 3 rash: 13 days 3

Weekly Monitoring Should Include:

• Fasting glucose and/or HbA1c
• Assessment for rash development
• Gastrointestinal symptoms (diarrhea, stomatitis, nausea)
• Signs of hypersensitivity reactions

Ongoing Monitoring (After Week 4)

• Continue glucose monitoring regularly (frequency based on glycemic control)
• Monitor for late-onset diarrhea (median onset of grade 3 events: 139 days) 3
• Assess for stomatitis, skin changes, and other adverse effects
• Regular clinical and radiological assessment of lesion response

Safety Considerations and Adverse Event Management

Most Common Adverse Events in PROS Patients

Based on the EPIK-P1 study in 57 PROS patients 1, 4:

• Diarrhea: 16% (all Grade 1)
• Stomatitis: 16% (including aphthous ulcers)
• Hyperglycemia: 12%
• Eczema, dry skin, alopecia: 5-7% each
• Cellulitis: 5%

Prophylactic Measures

Strongly consider prophylaxis before starting alpelisib:

• For rash prevention: Non-sedating antihistamines or steroids 3
• For hyperglycemia: Metformin (alone or in combination with other hypoglycemic agents was used in the majority of SOLAR-1 patients) 3
• Have antidiarrheal agents readily available

Dose Modifications

• Dose interruptions occurred in 11% of PROS patients (most commonly for dizziness and vomiting) 1
• Dose reductions occurred in 5% (for alopecia, memory impairment, soft tissue infection) 1
• Serious adverse events occurred in 12% of patients 1

Critical Safety Warnings

1. Severe hypersensitivity reactions can occur 1
2. Severe cutaneous adverse reactions require immediate attention 1
3. Pneumonitis is a potential serious complication 1
4. Colitis: Monitor for abdominal pain, mucus, or blood in stool; may require enteric-acting and/or systemic steroids 1
5. Embryo-fetal toxicity: Counsel adolescent females on effective contraception during treatment and for 1 week after last dose 1

Administration Details

Dosage Forms for Adolescents

• Tablets (preferred for 125 mg dose): Can be swallowed whole or prepared as oral suspension if swallowing difficulty exists
• Oral granules (50 mg packets): ONLY for patients prescribed 50 mg dose; do NOT use multiple packets or partial packets for higher doses 1
• Never combine tablets and granules to achieve prescribed dose

Missed Dose Instructions

• Can take within 9 hours of usual time with food
• After >9 hours: skip that day's dose, resume next day at usual time
• If vomiting occurs after dose: do not take additional dose that day 1

Expected Clinical Outcomes

Efficacy Data from PROS Patients

• 37.5% of patients achieved ≥20% reduction in target lesion volume at 24 weeks 4
• 97.3% of patients showed clinical improvement in at least one disease manifestation across multiple studies 5
• Radiological response (≥20% volume reduction) documented in 47.3% of evaluable cases in real-world evidence 5
• Additional clinical benefits observed independent of lesion volume reduction 4

Long-term Treatment

• 95% of EPIK-P1 patients remained on treatment for ≥6 months 1
• 79% remained on treatment for >1 year 1
• Treatment continues until disease progression or unacceptable toxicity 1

Key Clinical Pitfalls to Avoid

1. Inadequate early monitoring: The 15-day median onset of severe hyperglycemia and rash makes weekly monitoring in the first month non-negotiable
2. Missing baseline HbA1c screening: This is a critical exclusion criterion (must be <6.5%)
3. Incorrect dosing with oral granules: Do not attempt to use multiple 50 mg packets for higher doses due to unpredictable pharmacokinetics 1
4. Delayed recognition of colitis: Diarrhea can progress to serious colitis requiring steroids
5. Inadequate contraceptive counseling: Essential for adolescent females of reproductive potential

Note: All provided guideline evidence [3-6] pertains to alpelisib use in breast cancer, not PROS. The FDA drug label [1-1] and PROS-specific research [2-7,5] provide the definitive guidance for this pediatric indication, which received accelerated FDA approval specifically for severe PROS manifestations requiring systemic therapy.